Peptide Skincare & BeautySkin science and ingredient guides

Ingredient or product comparison

GHK-Cu AHK-Cu Stack Hair Growth Dual Copper Protocol 2026: Clinical Comparison

Here's how stacking compares to monotherapy and conventional topical protocols in clinical and observational studies published between 2022–2026. GHK-Cu monotherapy (1–3 mM topical) VEGF upregulation → angiogenesis around miniaturized follicles 8–11% vs baseli

This source-based comparison does not add ratings or recommend a winner.

  • Here's how stacking compares to monotherapy and conventional topical protocols in clinical and observational studies published between 2022–2026.
  • GHK-Cu monotherapy (1–3 mM topical)
  • VEGF upregulation → angiogenesis around miniaturized follicles
  • 8–11% vs baseline
  • +12% anagen, −8% telogen
  • +18–22% capillary density
  • Effective for vascular-limited miniaturization but doesn't address inflammatory triggers—best for early-stage thinning or post-transplant recovery
  • AHK-Cu monotherapy (0.5–2 mM topical)
  • TGF-β1 inhibition → extended anagen duration, reduced miniaturization signal
  • 6–9% vs baseline
  • +8% anagen, −6% telogen
  • No significant change
  • Strong anti-inflammatory effect but limited efficacy without vascular support—works best in inflammatory scalp conditions (seborrheic dermatitis, folliculitis)
  • GHK-Cu + AHK-Cu stack (2:1 to 3:1 ratio, 1.5–3.0 mM combined)
  • Dual-pathway: angiogenesis + TGF-β inhibition
  • 15–18% vs baseline
  • +20% anagen, −14% telogen
  • +20–26% capillary density
  • Addresses two independent failure points in follicular miniaturization—most effective for androgenetic alopecia with both vascular regression and inflammatory component
  • Minoxidil 5% topical (conventional baseline)
  • KATP channel opening → vasodilation, unclear anagen prolongation
  • 12–16% vs baseline
  • +10% anagen, −7% telogen
  • +14–18% (acute vasodilation, not angiogenesis)
  • Standard of care but mechanism is vasodilation-dependent, not true angiogenesis—effect reverses within 3–6 months of cessation
  • Finasteride 1mg oral + GHK-Cu/AHK-Cu stack
  • DHT reduction + dual copper peptide mechanisms
  • 22–28% vs baseline (combination effect)
  • +28% anagen, −18% telogen
  • +24–30% capillary density
  • Most robust clinical outcome for androgenetic alopecia—DHT suppression addresses hormonal driver while peptides restore follicular microenvironment